NASDAQ •
Healthcare •
Biotechnology •
Quote as of 05/08/2026
Company Profile
IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization159.16 mln
Float24.23 mln
Earnings Date08/18/2026
Piotroski F-Score
3
/ 9
Below average
1-Year Forecast
20.20
Transformational upside
Relative Strength
5
/ 100
Severely lagging
Debt / Equity
0.00
Debt-free
ROE
-61.74
Deeply negative
Dividend Yield
0.00%
No dividend
Business Description
OnKure Therapeutics is a drug development company working to create targeted treatments for cancer and other serious diseases. Its main drug in development, OKI-219, is designed to block a specific genetic mutation linked to tumor growth and is currently being tested in early-stage human trials for breast cancer and other solid tumors. Founded in 2011, the company is based in Boulder, Colorado.
